key: cord-0861096-g78dhcet
authors: Disse, Sigrid C.; Manuylova, Tatiana; Adam, Klaus; Lechler, Annette; Zant, Robert; Klingel, Karin; Aepinus, Christian; Finkenzeller, Thomas; Wellmann, Sven; Schneble, Fritz
title: COVID-19 in 28-Week Triplets Caused by Intrauterine Transmission of SARS-CoV-2—Case Report
date: 2021-12-24
journal: Front Pediatr
DOI: 10.3389/fped.2021.812057
sha: 774e954bcc32912b3e05a90612aa0df1a1fe0946
doc_id: 861096
cord_uid: g78dhcet

Since the beginning of the COVID-19 pandemic, in-utero transmission of SARS-CoV-2 remains a rarity and only very few cases have been proven across the world. Here we depict the clinical, laboratory and radiologic findings of preterm triplets born at 28 6/7 weeks to a mother who contracted COVID-19 just 1 week before delivery. The triplets showed SARS-CoV-2 positivity right after birth, developed significant leukopenia and early-onset pulmonary interstitial emphysema. The most severely affected triplet I required 10 days of high-frequency oscillatory ventilation due to failure of conventional invasive ventilation, and circulatory support for 4 days. Despite a severe clinical course in two triplets (triplet I and II), clinical management without experimental, targeted antiviral drugs was successful. At discharge home, the triplets showed no signs of neurologic or pulmonary sequelae. Placental immunohistology with SARS-CoV-2 N-protein localized strongly to syncytiotrophoblast cells and, to a lesser extent, to fetal Hofbauer cells, proving intrauterine virus transmission. We discuss the role of maternal viremia as a potential risk factor for vertical transmission. To the best of our knowledge, our report presents the earliest unequivocally confirmed prenatal virus transmission in long-term surviving children, i.e., at the beginning of the third trimester.

Whether vertical transmission (VT) is a possible route of SARS-CoV-2-infection in neonates has intrigued and worried medical specialists and families worldwide. After 2 years of global COVID-19-pandemic with >247 million cumulative cases of infected people worldwide (1) , reports on SARS-CoV-2 infections in preterm neonates are still scarce and the few published data suggest a mild to moderate course in neonates (2) (3) (4) (5) . Thus, we want to share the unique course, laboratory and radiological findings in a set of triplets with the scientific community. We report (1) a severe course of COVID-19 in two triplets, and (2) histopathologic analysis of the triplets' placenta, showing in utero-transmission of SARS-CoV-2.

A previously healthy Caucasian 36-year-old gravida 2 para 1 at 28 3/7 gestational weeks, had noted moderate respiratory symptoms for a few days and first tested positive for SARS-CoV-2 at a public test center (PCR test, EcoCare test center, Weiden). She presented to our Women's Hospital due to fever few days later, where the infection was confirmed (PCR test from nasopharyngeal swab; Allplex 2019-nCov, Seegene, Seoul, Korea). The pregnancy was intact with trichorionic triplets, conceived after intrauterine insemination. Maternal observation was uneventful, and she was administered two doses of steroids for fetal pulmonary maturation. She was discharged home > 24 h after administration of the second dose of steroids in a stable state. Few hours later, premature rupture of membranes occurred, and urgent C-section was performed at 28 6/7 weeks-8 days after the mother first tested positive for SARS-CoV-2. The triplets were delivered without complications and adaptation was unproblematic in all three (triplet I: male-birthweight 1,150 g, APGAR scores 8/9 and 9 at 1, 5, and 10 min; triplet II: female−990 g, APGAR scores 8/9 and 9; triplet III: female-930 g, APGAR scores 7/9 and 9). Physical examination showed eutrophic preterm newborns without any externally visible anomalies. They were referred to our neonatal intensive care unit (NICU) on non-invasive intermittent positive pressure ventilation (NIPPV) in closed incubators, requiring none or low concentrations of supplementary oxygen, and received standard neonatal care. Following strict hygiene precautions, both parents were only allowed to have any contact to the children after they tested negative twice, and until symptoms of COVID-19 had resolved completely. Calculated antibiotic therapy was initiated directly after delivery; the blood cultures remained sterile. The children showed progressive leukopenia but low CrP and IL-6 values ( Table 1) . RT-PCR assays for SARS-CoV-2 were performed from nasopharyngeal swabs immediately after birth, showing positive results in triplet I and III, and repeatedly thereafter ( cystic and linear radiolucencies and signs of lung hyperinflation, clearly distinct of prematurity-related acute respiratory distress syndrome (pmARDS) but resembling pulmonary interstitial emphysema (Figure 1) . Triplet I was switched to high-frequency oscillation ventilation (HFOV) shortly after intubation due to failure of conventional invasive ventilation and required high concentrations of supplementary oxygen ( Table 1) . For circulatory support, he received dopamine intravenously for DOL 2-6. Due to stable conditions in all three, we decided against experimental administration of targeted antiviral drugs. Triplet I was extubated successfully on DOL 15 following administration of a single dose of dexamethasone (0.1 mg/kg). Triplet II required continuous positive airway pressure (CPAP) support via highflow nasal cannulas with ambient air until a corrected age of 36 4/7 weeks. Triplet I and II required intravenous ibuprofen for closure of a hemodynamically relevant patent ductus arteriosus. Serial cranial ultrasounds were normal in all children. Enteral feeding was initiated with formula for 4 days, then pasteurized maternal breast milk was available. A sample of breast milk tested negative for SARS-CoV-2, using RT-PCR. The triplets showed no signs of feeding intolerance. We discharged them at a corrected gestational age of 38 weeks, breathing spontaneously and without neurological symptoms.

Analysis of maternal blood taken 5 days after delivery showed a substantial viral load (Ct-value 34.5, estimated ∼100-1,000 GE/ml, Ridagene SARS-CoV-2, R-biopharm, Darmstadt, Germany), despite a strong Immunoglobulin A immune response (IgA-Ratio >10; positive >1.1) and positive IgG immune response (IgG-ratio 1.9; positive > 1.1, Euroimmun, Lübeck, Germany). RT-PCR from the serum of the triplets (100 ul serum each) could not detect SARS-CoV-2 specific RNA in the blood, as a possible sign of systemic infection. Blood samples taken after birth in the triplets showed no hint toward an already detectable IgG response transmitted via the placenta (triplets I-III, IgG, all index ratios <0.1 respectively). Ten weeks after birth, triplet I and III showed medium to high SARS-CoV-2 specific IgG but only low to no IgA response (Triplet I IgG 3.9, IgA 1.11, triplet III IgG 6.1, IgA 0.4). Triplet II, with severe clinical course, had no SARS-CoV-2 specific immune response at this time point (IgG 0.7; IgA 0.4). Surprisingly, viral load and the duration of virus persistence showed a strong association with disease severity: In triplet II, five nasopharyngeal swabs or tracheal aspirate specimens tested positive during the hospital stay, for the last time on DOL 25; among the five positive tests, two showed Ct-values <30 indicating a high viral load. Triplet I had seven positive tests, among which six showed Ct values <30, while triplet III had only two positive tests on DOL 1 and 2, both with low viral load.

Macroscopic examination showed trichorionic triamniotic fused placentas, weighing 770 g and measuring 26 × 28 × 3 cm. The cut surface of the placenta as well as the amnion were unremarkable. Histologically, placental villi revealed different maturation status, discrete intervillous fibrin deposition (Figure 2) , and focal degeneration of the villi. No massive intervillous fibrin depositions were noted. In some intermediate and stem villi, occlusive changes in the vessels were obvious. Additionally, focal intervillous histiocytic aggregates were seen, compatible with chronic histiocytic intervillositis (Figure 2) . These aggregates showed minimal regional differences, in line with the different viral loads of the fetuses. Immunohistology analysis of the triplets' placenta after discharge was performed as follows: For the detection of SARS-CoV-2 N-protein, 4 um thick tissue sections of paraffin embedded placentas (including normal placentas) we used the monoclonal mouse anti-SARS-CoV-2 N-protein antibody (clone N-IH-H5, 1:200, Mediagnost, Reutlingen, Germany). Immunohistochemical analysis was performed on an automated immunostainer following the manufacturer's protocol (Benchmark; Ventana Medical Systems, Tucson, AZ) and using the ultraView detection system (Ventana) and diaminobenzidine as substrate. Tissue sections were counterstained with hematoxylin. Results: SARS-CoV-2-Nprotein was detected by using a monoclonal antibody against the N-protein of SARS-CoV-2. The membranes of numerous syncytiotrophoblast cells revealed a strong, often homogeneous positivity. Additionally, single intervillous macrophages, Hofbauer cells and stroma cells were also found to express the SARS-CoV-2 N-protein. Placenta tissue of healthy triplets was completely negative (Figure 3) . When qRT-PCR was performed from paraffin-embedded placenta we found a high Ct-value of 16 for the detection of the N-gene. In addition, the ACE2 receptor was stained by using the mouse anti-ACE2 antibody (Novusbio/R&D Systems, clone #171606, 1:2000) and the ultraView detection system (Ventana) mentioned above. ACE2 was found to be expressed in syncytiotrophoblasts, villous cytotrophoblasts, villous stromal cells, and some stromal cells and macrophages within the decidua, corresponding well to the SARS-CoV-2 infected cell types within the placenta (Figure 3 ). placenta and the fetal side were affected as Hofbauer cells are macrophages of fetal origin (7); syncytiotrophoblast cells are epithelial cells in direct contact with maternal blood (8). We did not analyse cord blood or amniotic fluid. The following aspects additionally support congenital infections: (1) delivery via C-section under maternal general anesthesia, minimizing the possibility of contact with virus particles from exhaled air; afterwards, immediate maternal quarantine until she tested negative twice and symptoms resolved completely; (2) positive tests in triplets I and III by PCR from swabs taken directly after birth and each triplet had at least two positive tests, making 

The lack of a detectable immune response in the triplets directly after birth can be explained by the short time span between documented maternal infection and delivery (i.e., 1 week) as IgG production in pregnant women does not peak before 30 days after symptom onset (9) . Additionally, Edlow et al. (10) reported that transplacental transfer of SARS-CoV-2 antibodies was lower than compared to influenza-HA-specific antibodies, suggesting inefficient transplacental transfer of antibodies against SARS-CoV-2. As well, a German study in 16 mothers with COVID-19 showed lower or the same antibody levels against SARS-CoV-2 in umbilical cord blood as compared to maternal blood (11) . In accordance with the literature, our triplets I and III showed a seroconversion to IgG after 10 weeks; peaks in infant IgG production following perinatal infections were observed after 8 weeks in a term and in a preterm infant of 31 weeks (12) . Whether the low IgG levels in our triplet II contributed to the child's severe course of disease is unclear; serum levels will be controlled at the next venipuncture indicated.

Two published reports on COVID-19 in triplet pregnancies (13, 14) might raise concern for an elevated risk of VT in multiple pregnancies: A set of triplets was delivered via C-section at 30 5/7 weeks due to fetal deterioration and placental insufficiency. The heaviest triplet tested positive for SARS-CoV-2 on DOL 3 after an initially negative test (13, 15) . Two triplets died due to sepsis and pmARDS. The SARS CoV-2 positive triplet required invasive ventilation as well but was later discharged in good health. No further tests were performed. Another set of triplets was born at 32 5/7 weeks by emergency C-section (14) , due to maternal active labor and abnormal fetal presentation. All three tested positive by nasopharyngeal swabs on postnatal DOL 1 and 5. One triplet required respiratory support until DOL 3; otherwise, the neonates were asymptomatic. As neither amniotic fluid, nor the placenta or cord blood were evaluated, intrauterine transmission was suspected but could not be proven, either. Thus, currently available literature does neither provide consistent evidence for an elevated risk of congenital COVID-19 in multiple pregnancies, nor unequivocal proof of intrauterine transmission in the few cases suspicious for VT.

Previous reports on preterm neonates with COVID-19 are scarce: A Belgium 26-week preterm neonate contracted COVID-19 most likely through horizontal transmission on DOL 6. She received NIPPV prior to infection with SARS-CoV-2 and remained stable on CPAP support afterwards (2) . A preterm born at 33 weeks reported as "possible VT" first tested positive by throat swab 16 h after birth, required 12 h of ventilation rather due to maternal sedation, and had a normal chest radiograph (16) . A preterm of 32 weeks (17), born to a mother with a fatal course of COVID-19, fulfills the criteria for a "probable congenital infection" (6) due to detection of the virus in amniotic fluid but remained asymptomatic. In a UK neonatal SARS-CoV-2 cohort including 66 neonates (16 preterm) (5), two neonates were described with a "possible VT." They had a positive nasopharyngeal swab 12 h after birth but received no further tests. In this cohort, incidence rates were higher in preterm compared to term neonates; yet, for preterm babies <32 weeks and <28 weeks, the confidence intervals were broad as they relied on only one case, respectively. One preterm neonate required invasive ventilation (at 36 weeks gestational age), indicating that most preterm neonates generally cope with SARS-CoV-2 infections well (5). This is supported by data from a cohort of 582 infected children identified through a European multicentre study including 25 countries (18): The neonatal subcohort (n = 35) comprised three preterm neonates, of which only one required mechanical ventilation-probably due to prematurity. Furthermore, one of the largest cohorts of neonates born to mothers with confirmed or suspected SARS-CoV-2 infection (19) (n = 100 mothers, n = 101 newborns) comprised 11 preterm babies, but there was neither evidence of a symptomatic neonatal infection nor of VT.

In a 35 week-preterm neonate, investigations showed an unequivocally confirmed transplacental infection with SARS-CoV-2 (20): The virus was detected in maternal and neonatal blood, in placental tissue, amniotic fluid and in multiple maternal and neonatal swabs. The child was delivered by urgent C-section, required resuscitation, and few hours of mechanical ventilation but showed no pulmonary manifestations thereafter. A cerebral MRI due to neurologic symptoms showed important white matter injury, estimated to be due to vascular inflammation caused by the SARS-CoV-2 infection (20). Pronounced inflammation due to SARS-CoV-2 has also been reported in two at-term placentas, both at the cytokine and at the genetic level (21) . Placental SARS CoV-2 infectionas demonstrated e.g., by systematic investigation of 22 SARS CoV-2 positive placentas (22)is consistently associated with chronic histiocytic intervillositis, trophoblast necrosis (22) (23) (24) and it is frequently accompanied by fibrin depositions (23, 25) . These findings-chronic histiocytic intervillositis and trophoblast necrosis-were shown in both liveborn and stillborn neonates infected by transplacental transmission (24) . The detection of complement C4d at the villous surface of infected placentas suggests a key role of the complement system in this process (25) . It should also be noted that the extensive placental damage induced by SARS CoV-2 has caused pathologists to be concerned about potential neurologic sequelae in affected children (25) . Schwartz et al. further showed that Hofbauer cell positivity is not required for transplacental fetal infections (22) . Another group found that maternal clinical COVID-19 symptoms did not predict the severity of the SARS-CoV-2related placental signature (26) . In summary, currently available data emphasize the rarity of COVID-19 in preterm neonates, of a severe clinical course in preterm neonates associated with SARS-CoV-2, and of extremely rare in-utero-transmission of the virus.

Our investigations point to the mechanism by which the virus was most likely transmitted to the children-maternal viremia-presuming presence of the virus in maternal blood already before delivery. As hypothesized by others (21) , the virus probably spreads via the bloodstream to the uterus, and then infects the fetuses. Generally low and transient viremia in adults with symptoms of COVID-19 is estimated to occur in ∼1% of patients (27, 28) . A cohort study in adults showed higher plasma viral loads in critically ill as compared to less severely affected patients (29) . Hitherto, viremia has not been investigated systematically in pregnant women with COVID-19: Numerous neonatal cases with suspected VT (3, 5, 16, 30, 31) did not investigate maternal viremia, nor was the subject addressed in a large number of pregnancies with uneventful neonatal outcomes (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . Hence, the significance of viremia in pregnant women is poorly understood. The Shah classification (6) also does not address the subject. In the cohort study conducted by Edlow et al. (10) , there were no cases of viremia in maternal or in umbilical cord blood and no cases of VT. The authors concluded that lack of viremia in mothers may be protective against neonatal congenital infections (10) . As an alternative mechanism for virus transmission, infection of amniotic fluid swallowed by the fetuses has been proposed (14) .

While our investigations have shown intrauterine virus transmission unequivocally, we cannot establish the nature of the relationship between the viral infection and disease severity with certainty (association vs. causality): Preterm neonates born at 29 weeks may require HFOV and/or circulatory support, irrespective of COVID-19. Thus, prematurity very likely contributed significantly to the observed clinical course. Yet, several factors ["Bradford-Hill criteria" for causality (43) ]) argue in favor of an additional, major contributing role of COVID-19: (1) We observed a biological gradient between the triplets for viral load/duration of virus persistence on the one hand, and severity of clinical symptoms, laboratory and radiological findings on the other ("dose-response-relationship"); (2) biological plausibility: Abundant detection of viral RNA in throat swabs and tracheal aspirate, and production of unusually thick oral secretions make pulmonary manifestations of COVID-19 in the triplets plausible; (3) coherence: The observed pulmonary and radiologic findings are not contradictory to the pulmonary manifestations in older children or adults. Additionally, there are no other explanatory factors for a severe course of disease, such as missing fetal lung maturation, bacterial infections and/or long persistence of premature rupture of membranes.

The triplets are followed-up in our Pediatric Neurodevelopmental Center. At corrected 9 months, triplet I developed horizontal nystagmus and showed moderate developmental delay; all investigations including cerebral MRI and electroencephalography were normal. Neurologic exam at follow-up was normal in triplets II and III and they have reached their developmental milestones according to their corrected age. Both parents are very supportive of the triplets.

We acknowledge some limitations: We did not evaluate maternal or neonatal samples for coronavirus mutations. We tested neither umbilical cord blood nor amniotic fluid for SARS-CoV-2 virus RNA/antibodies.

In conclusion, our report has several important clinical implications: (1) Counseling pregnant women should include to inform mothers about the rare possibility of a severe course of COVID-19 in (preterm) neonates. (2) Our triplets' cases show that vertical transmission of SARS-CoV-2, though rare, may occur as early as at the beginning of the third trimester. As new mutations have emerged, their pathogenicity with regard to pregnant women and their babies remains to be elucidated. (3) Published cases of affected neonates underline the importance of preventive measures, especially in high-risk expecting mothers. In this context, close follow-up is particularly advisable in mothers with multiple pregnancies. (4) Our observation of maternal viremia in association with severe neonatal COVID-19 warrants systematic investigation in larger cohorts of pregnant women in order to evaluate potential usability of maternal viremia as a marker to identify high-risk neonates in advance-as well as potential drivers for maternal viremia and in-utero virus transmission.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements. Written informed consent was obtained from the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

SD performed data collection, data interpretation, did the literature search, and drafted the manuscript. CA and SD conducted the microbial workup. TM and KK performed histopathologic workup including immunohistology. KA helped with the radiographic images. SW contributed to literature search, data interpretation, and critically reviewed the manuscript. TF, CA, KA, RZ, TM, KK, and AL contributed to data interpretation and critically reviewed the manuscript. FS contributed to data interpretation, critically reviewed the manuscript, and supervised the clinical management. SD, KA, and FS had full access to all clinical data and verified it. All authors approved the final version of the manuscript for submission.

World Health Organization. WHO Coronavirus (COVID-19) Dashboard. (2021)

COVID-19 in a 26-week preterm neonate

Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn

Antibodies in infants born to mothers with COVID-19 pneumonia

Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance

Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates

Hofbauer Cells: Their role in healthy and complicated pregnancy

Vascular Biology of the Placenta

Severe acute respiratory syndrome coronavirus 2 serology levels in pregnant women and their neonates

Assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic

SARS-CoV-2 in pregnancy and possible transfer of immunity: assessment of peripartal maternal and neonatal antibody levels and a longitudinal follow-up

Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: prospective cohort study

Maternal and fetal effects of COVID-19 virus on a complicated triplet pregnancy: a case report

Is vertical transmission of SARS-CoV-2 infection possible in preterm triplet pregnancy? a case series

Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes

Severe COVID-19 during pregnancy and possible vertical transmission

Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection

The ability of the neonatal immune response to handle SARS-CoV-2 infection

Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center

Transplacental transmission of SARS-CoV-2 infection

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Hofbauer cells and COVID-19 in pregnancy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting pregnant women and the fetus, intrauterine transmission, and placental pathology during the coronavirus disease 2019 (COVID-19) pandemic: it's complicated

Chronic histiocytic intervillositis with trophoblast necrosis is a risk factor associated with placental infection from coronavirus disease 2019 (COVID-19) and intrauterine maternal-fetal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in live-born and stillborn infants

Defining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placentitis

Unique severe COVID-19 placental signature independent of severity of clinical maternal symptoms

Evidence for and against vertical transmission for severe acute respiratory syndrome coronavirus 2

Detection of SARS-CoV-2 in different types of clinical specimens

Dynamics of blood viral load is strongly associated with clinical outcomes in coronavirus disease 2019 (COVID-19) patients: a prospective cohort study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vertical transmission in neonates born to mothers with coronavirus disease 2019 (COVID-19) pneumonia

Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China

Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission

No intrauterine vertical transmission in pregnancy with COVID-19: a case report

Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis

Maternal and neonatal outcomes of pregnant women with coronavirus disease 2019 (COVID-19) pneumonia: a case-control study

Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals

Placental abruption in a twin pregnancy at 32 weeks' gestation complicated by coronavirus disease 2019 without vertical transmission to the babies

Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China

A pregnant woman with COVID-19 in Central America

Modern Epidemiology

The triplets' parents provided full written informed consent to publication of the case report, including the radiographies. The authors thank PD Dr. D. Wachter, Institute for Pathology at Weiden Hospital, for his assistance with the histopathologic analysis.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2021 Disse, Manuylova, Adam, Lechler, Zant, Klingel, Aepinus, Finkenzeller, Wellmann and Schneble. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.